Patient Demographics1
(N=1301)
- Patient demographics were generally comparable across regions1
Patient Treatment History1
(N=1301)
- 2L, second-line; 3L, third-line; 4L, fourth-line.
- aCAR T-cell therapies percentages do not include patients from Spain or UK.1
bBsAb percentages do not include respondents from Spain, UK, or Japan.1
cIncludes B-cell maturation antigen (BCMA)-directed or G protein–coupled receptor class C group 5 member D (GPRC5D)-directed BsAbs.1
- Patient demographics were generally comparable across regions1
HCP Practice Characteristics
HCP practice characteristics were broadly similar across regions (N=983)1
- dIn the US, HCPs were defined as academic/COE if 50% or more of their practice was based in a hospital with academic affiliation and/or a specialized cancer center. In other countries, HCPs were defined as academic/COE if 50% or more of their practice was based in a COE or teaching hospital, or a cancer center if in France. HCPs were defined as community if their practice was based in less than 50% of these types of institutions.2
- eCAR T-cell therapies percentages do not include respondents from UK.1 fIncludes BCMA-directed or GPRC5D-directed BsAbs.1 gBsAb percentages do not include respondents from Japan.1
- dIn the US, HCPs were defined as academic/COE if 50% or more of their practice was based in a hospital with academic affiliation and/or a specialized cancer center. In other countries, HCPs were defined as academic/COE if 50% or more of their practice was based in a COE or teaching hospital, or a cancer center if in France. HCPs were defined as community if their practice was based in less than 50% of these types of institutions.2
Learn about the key survey insights and priority calls to action
References
- Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence. 2025;2025(19):1089-1104. Published April 2, 2025. Taylor & Francis Ltd. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com.
- Data on file. Pfizer Inc., New York, NY.